Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellectar Biosciences, Inc. (NASDAQ: CLRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including registration statements, current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Cellectar’s late-stage clinical oncology programs, capital structure and risk factors.
Through forms such as Form S‑1 and S‑1/A, investors can review descriptions of the company’s Phospholipid Drug Conjugate (PDC) platform, its lead radiotherapeutic candidates iopofosine I 131, CLR 121125 (CLR 125) and CLR 121225 (CLR 225), and the clinical and preclinical data supporting these programs. These registration statements also outline unit offerings, warrant terms, use of proceeds and the impact of actions like the one‑for‑thirty reverse stock split.
Form 8‑K current reports document material events, including scientific advice from the European Medicines Agency’s Scientific Advice Working Party on a potential Conditional Marketing Authorization for iopofosine I 131 in Waldenstrom’s macroglobulinemia, warrant inducement transactions, reverse stock split implementation, and preliminary financial information. Earnings press releases furnished as exhibits to 8‑Ks provide narrative overviews of quarterly performance and corporate updates.
On Stock Titan, CLRB filings are supplemented with AI‑generated highlights that summarize key points from lengthy documents, helping users quickly identify information on clinical milestones, regulatory designations, financing transactions and changes to capital structure. Real‑time updates from EDGAR ensure that new Cellectar filings, including future 10‑K annual reports, 10‑Q quarterly reports and any Form 4 insider transaction disclosures, are incorporated as they become available, while the full text remains accessible for detailed review.
Cellectar Biosciences reported a narrower net loss for the year ended December 31, 2025 while advancing its radiotherapeutic pipeline. Net loss was
Cash and cash equivalents were
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing cancer drugs based on its phospholipid ether drug conjugate (PDC) platform, which is designed to deliver radioactive and other payloads directly into tumor cells while sparing healthy tissue.
The lead radioconjugate, iopofosine I 131, showed strong results in Waldenstrom macroglobulinemia, with a 58.2% major response rate and 83.6% overall response rate in a pivotal CLOVER-WaM study of heavily pretreated patients, and has Breakthrough Therapy, Fast Track, Orphan Drug, PRIME and Rare Pediatric Disease designations across multiple indications. The FDA has outlined a path that could support accelerated and full approval, contingent on a Phase 3 confirmatory trial. Additional radioconjugate programs CLR 121125 and CLR 121225 are advancing toward or into early clinical studies in solid tumors such as triple-negative breast and pancreatic cancer.
Cellectar Biosciences, Inc. received an updated ownership report from Bleichroeder-related entities on a Schedule 13G/A. Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 200,000 common shares, representing 4.61% of the company’s common stock.
The filing notes that Bleichroeder LP, a registered investment adviser, is deemed the beneficial owner because it manages these holdings for various clients. Those clients have the right to receive dividends and sale proceeds. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Cellectar Biosciences.
Cellectar Biosciences, Inc. received an amended Schedule 13G showing that investment entities associated with Rosalind Advisors, Inc. report beneficial ownership tied to up to 247,715 common shares, representing 5.5% of the class, as of an event date of 12/31/2025.
The percentage is based on 4,240,134 common shares outstanding as of November 10, 2025. The filing explains that this figure reflects shares issuable upon full conversion of preferred stock and exercise of warrants, but actual ownership is contractually capped by blockers limiting conversions above 9.99% and warrant exercises above 4.99% of outstanding common stock.
Cellectar Biosciences, Inc. (CLRB)Hexstone Capital LLC and its managing member Brendan O’Neil, updating their ownership. The filing states this is an exit filing because each reporting person now beneficially owns less than five percent of Cellectar’s common stock.
The reporting persons disclose beneficial ownership of 216,130 shares of common stock, representing 4.9%–4.99% of the class, based on 4,240,134 shares outstanding as of November 21, 2025. This includes 125,000 shares of common stock and 91,130 shares issuable upon exercise of Series A warrants, with additional warrant shares blocked by a 4.99% beneficial ownership limitation. Hexstone holds the shares directly; O’Neil may be deemed to beneficially own them through Hexstone. The filers certify the securities are not held to change or influence control of the company.
Cellectar Biosciences director John Neis reported selling 198 shares of the company’s common stock on December 12, 2025 at a weighted average price of $3.6969 per share. The shares were sold in multiple trades at prices ranging from $3.631 to $3.70.
Following this transaction, he is reported as beneficially owning 10 shares of common stock indirectly, held through Advantage Capital Wisconsin Partners I, Limited Partnership. The reported share amount reflects adjustments for prior reverse stock splits in 2018, 2022, and 2025.
Cellectar Biosciences is registering up to 2,096,188 shares of common stock for resale by existing holders, all issuable upon exercise of previously issued Series I and Series II Inducement Warrants. These resale shares will be sold from time to time by the selling stockholders, and the company will not receive proceeds from their sales, only from any cash warrant exercises. Assuming full exercise of the Inducement Warrants, shares outstanding would be 6,336,322.
The October 2025 warrant inducement and related new warrants generated approximately $5.8 million in gross proceeds, and a July 2025 underwritten offering added about $6.9 million. As of September 30, 2025, estimated cash was about $12.6 million, which management believes can fund operations into the third quarter of 2026, while explicitly highlighting substantial doubt about continuing as a going concern without new capital or a strategic transaction.
Clinically, lead asset iopofosine I 131 for Waldenstrom macroglobulinemia has FDA Breakthrough Therapy designation and EMA scientific advice indicating a conditional marketing authorization filing "could be acceptable," potentially allowing commercial availability in EMA countries as early as 2027, subject to successful submissions and studies.
Cellectar Biosciences (CLRB) furnished an 8-K announcing it issued a press release with third‑quarter 2025 financial results and a corporate update. The press release covers the quarter ended September 30, 2025 and is provided as Exhibit 99.1 dated November 13, 2025. The company’s common stock trades on The Nasdaq Capital Market under the symbol CLRB.
Cellectar Biosciences reported a narrower quarterly loss and lower expenses while highlighting liquidity risks. For the three months ended September 30, 2025, net loss was $4.44 million, down from $14.66 million a year ago, as operating expenses fell to $4.85 million from $13.33 million. For the nine months, net loss was $16.50 million versus $42.23 million in 2024.
Cash and cash equivalents were $12.55 million at September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern and estimated available liquidity of approximately $15.6 million as of the issuance date, with runway potentially extending beyond the third quarter of 2026 if actions are taken.
Financing activity included a $6.9 million underwritten offering on July 2, 2025 and approximately $2.5 million of gross proceeds from warrant exercises on June 6, 2025. A 1‑for‑30 reverse stock split became effective on June 24, 2025. Shares outstanding were 3,192,040 as of September 30, 2025, and 4,240,134 as of November 10, 2025. The FDA granted Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia on June 4, 2025.
Cellectar Biosciences filed an S-1 for a resale of up to 2,096,188 shares of common stock by selling stockholders. These shares are issuable upon exercise of previously issued Inducement Warrants from an October 2025 warrant inducement transaction. The company states it will not receive proceeds from selling stockholder resales; it would receive cash only if holders exercise the warrants.
The Inducement Warrants consist of two series, each immediately exercisable at $6.00 per share: Series I (up to 1,048,094 shares) expiring October 8, 2030, and Series II (up to 1,048,094 shares) expiring April 8, 2027. Cellectar previously received approximately $5.8 million gross proceeds from the cash exercise of certain existing warrants and the sale of the Inducement Warrants tied to this transaction.
As context, the company lists 6,336,322 shares outstanding after completion of this offering assuming full warrant exercise. Cellectar’s common stock trades on Nasdaq as “CLRB”; on October 17, 2025, the last reported sale price was $4.50.